Famciclovir (Famvir), in a single-dose treatment, has been proven to stop the progression to a full-blown outbreak of recurrent genital herpes (rGH) as well as to shorten the duration of the outbreak. Thus far, famciclovir is the only treatment effective for rGH in a single dose. A multicenter, randomized, double-blind, placebo-controlled study compared the 1-g dose for 1-day famciclovir with placebo. When patients with rGH initiated treatment with famciclovir within 6 hours of the first sign of outbreak, famciclovir reduced healing time of nonaborted lesions by 2 days. A higher percentage of patients experienced aborted lesions in the famciclovir group (23.3%) than in the placebo group (12.7%). In fact, patients taking famciclovir experienced a reduction in duration of all symptoms: itching, pain, burning, tingling, and tenderness3.3 days versus 5.4 days in the placebo group. Lead investigator Fred Aoki, MD, of the University of Manitoba (Canada), concluded, "Famvir was effective in a single-day dose because it provided a full course of therapy upfront when the virus is most active."
Ms. Farley is a freelance medical writer based in Wakefield, RI.
One study linked multiple pregnancies to an increased risk of developing atrial fibrillation later in life, and another investigated the association between premature delivery and cardiovascular disease.
Clinical features with downloadable PDFs